Hepatitis C treatment eligibility among HIV–hepatitis C virus coinfected patients in Oregon: a population-based sample.
Approximately 287,000 individuals in the USA are coinfected with HIV and hepatitis C. Recently, new hepatitis C regimens have become available, increasing rates of sustained virologic response in the monoinfected, with studies evaluating their success in the coinfected under way. Previous investigat...
| Publicado en: | AIDS Care Vol. 26; no. 9; pp. 1178 - 1186 |
|---|---|
| Autores principales: | , , , , |
| Formato: | research tables/charts Journal Article |
| Publicado: |
Taylor & Francis Ltd
Sep2014
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=96673093&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 96673093 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 09540121 AAE jtl: AIDS Care issn: 09540121 maglogo: N pubinfo: dt: Sep2014 vid: 26 iid: 9 pid: 377 pub: Taylor & Francis Ltd place: Philadelphia, Pennsylvania artinfo: ui: 96673093 103962809 103962809 10.1080/09540121.2014.892563 96673093 ppf: 1178 ppct: 8 formats: fmt: @attributes: type: P tig: atl: Hepatitis C treatment eligibility among HIV–hepatitis C virus coinfected patients in Oregon: a population-based sample. aug: au: Maier, Marissa M. He, Haiou Schafer, Sean D. Ward, Thomas T. Zaman, Atif affil: Division of Infectious Diseases, Oregon Health and Sciences University, Portland, OR, USA sug: subj: HIV Infections Physiopathology Hepatitis C Therapy Patient Selection Comorbidity Oregon Disease Surveillance Demography Retrospective Design Cross Sectional Studies Random Sample Descriptive Statistics Confidence Intervals Multiple Logistic Regression P-Value Chi Square Test Data Analysis Software Odds Ratio Adult Middle Age Aged Female Male Human Adult: 19-44 years Middle Aged: 45-64 years Aged: 65+ years Female Male ab: Approximately 287,000 individuals in the USA are coinfected with HIV and hepatitis C. Recently, new hepatitis C regimens have become available, increasing rates of sustained virologic response in the monoinfected, with studies evaluating their success in the coinfected under way. Previous investigators estimated eligibility for hepatitis C therapy among the coinfected patients, but all had significant methodological limitations. Our study is the first to use a multi-year, statewide, population-based sample to estimate treatment eligibility, and the first to estimate eligibility in the setting of an interferon-free regimen. In a population-based sample of 161 patients infected with HIV and hepatitis C living in Oregon during 2007–2010, 21% were eligible for hepatitis C therapy. Despite the anticipation surrounding an interferon-sparing regimen, eligibility assuming an interferon-free regimen increased only to 26%, largely due to multiple simultaneous contraindications. Obesity was described for the first time as being associated with decreased eligibility (OR: 0.11). Active alcohol abuse was the most common contraindication (24%); uncontrolled mental health (22%), recent injection drug use (21%), poor antiretroviral adherence (22%), and infection (21%) were also common excluding conditions. When active drug or alcohol abuse was excluded as contraindications to therapy, the eligibility rate was 34%, a 62% increase. Assuming an interferon-free regimenandthe exclusion of active drug or alcohol abuse as contraindications to therapy, the eligibility rate increased to 42%. Despite the availability of direct-acting anti-viral regimens, eligibility rates in HIV–hepatitis C virus (HCV) coinfection are modest. Many factors precluding hepatitis C therapy are reversible, and targeted interventions could result in increased eligibility. pubtype: Academic Journal doctype: research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|